Advancing Surgical Techniques in Neuroendocrine Tumors
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Building Upon an “Era of Therapeutic Refinement” in Pancreatic Cancer
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Pancreatic Cancer Incidence Has Risen, Yet Survival Outcomes Have Improved
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors
Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.
Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC
For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.
Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma
The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma
“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD
Ensuring Safe Bispecific Antibody Use in Lymphoma at Community Practices
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Addressing Gaps in Education for Non–Clear Cell RCC
A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.
FDA Approves FoundationOne Liquid CDx as Diagnostic Tool for NSCLC
FoundationOne Liquid CDx has been approved as a diagnostic tool for tepotinib in patients with non–small cell lung cancer METex14 skipping alterations.
Palliative Care May Improve Mental Health in Pancreatic Cancer Diagnoses
The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.
Blood Testing for Lung Cancer May Address Inadequate Screening Utilization
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Pembrolizumab/Cisplatin Combo Shows Promise in Small Cell Bladder Cancer, Neuroendocrine Prostate Cancer
Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.
Managing Pancreatic Cancer Through Risk Factors, Diagnosis, and AEs
A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.
Nivolumab/Ipilimumab Earns CHMP Recommendation for Colorectal Cancer
The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.
Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma
Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL
“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.
BTK Inhibitor Treatment Options Across the Lymphoma Landscape
Clinicians focused on CLL, follicular lymphoma, and MCL gathered during a Frontline Forum to discuss the use of BTKi in each respective disease state.
Radical Remission Multimodal Intervention Improves QOL in Patients With Cancer
Patients with any type of cancer showed better QOL after undergoing the radical remission multimodal intervention method.
